Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation and it is thought that neutrophils play a major role in the disease pathogenesis. Genetic polymorphism of the vitamin-D-binding protein (VDBP) gene is considered one of the candidates for variation in susceptibility to COPD. To evaluate the potential influences of VDBP gene polymorphisms on COPD, a case-control study was conducted in the Han population of north-east China. The VDBP polymorphic site was genotyped in 100 COPD patients and 100 controls. Genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism. A significantly higher proportion of VDBP-1F homozygosity was found in COPD patients, while the frequency of VDBP-2 homozygosity was significantly lower in COPD patients, which seemed to suggest that VDBP-2 homozygocity provided a protective effect. These data suggest that the VDBP gene may be involved in COPD susceptibility in Chinese Han population.
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by expiratory airflow obstruction and hyperinflation, and is becoming the most prevalent respiratory disease in China. 1 Tobacco smoking is the greatest risk factor for the development of COPD, although approximately 85% of smokers do not develop clinically relevant airflow obstruction. 2 Several epidemiological studies have suggested that genetic factors are likely to have a role in determining an individual's susceptibility to COPD. 3 -6 Polymorphisms in several genes have been shown to be involved in the development of COPD and one such candidate is the vitamin D binding protein (VDBP) gene. 7 Vitamin D binding protein is a multifunctional, polymorphic 55 kDa protein that acts both as a precursor of macrophage-activating factor and as a cochemotaxin for phagocytic cells, 8 -10 indicating a role in chronic inflammatory responses in the lung. The VDBP gene has been localized to human chromosome 4q11-q13, 11 and exhibits considerable genetic Vitamin D binding protein variants and COPD variability due to its three polymorphic alleles (1F, 1S and 2) and > 124 rarer alleles. 12 An important factor in investigating the role of VDBP is the variation in allele frequency between populations. The aim of the present study was, therefore, to evaluate any relationship that may exist between VDBP allele frequency and the risk for COPD in the Han Chinese population.
Patients and methods

PATIENTS
The study group consisted of adults who were diagnosed with COPD (according to the guidelines of The American Thoracic Society 13 ) at the Second Affiliated Hospital of Harbin Medical University, Harbin, China. Unrelated healthy Han Chinese adults with no history of COPD were enrolled as controls. Patients and healthy controls were both recruited from the Heilongjiang Province of China between January and October 2009. The study was approved by the Ethics Committee of Harbin Medical University and adhered to the tenets of the Helsinki Declaration. Additionally, written informed consent was obtained from patients and controls.
LUNG FUNCTION TESTS
Lung function tests were carried out for all patients and controls and the use of bronchodilators was prohibited for at least 12 h before the tests were performed. The following pulmonary function data were calculated: (i) the percentage of predicted forced expiratory volume in 1 s (FEV 1 %pred) and forced vital capacity (FVC); (ii) the residual volume divided by the total lung capacity; and (iii) the diffusing capacity of the lung for carbon monoxide taken with patients in a stable condition (not at a time of exacerbation of COPD). The existence of COPD was confirmed with FEV 1 < 80%pred and FEV 1 /FVC < 70%; healthy controls were required to have FEV 1 > 85%pred and FEV 1 /FVC > 75%.
DNA EXTRACTION AND GENOTYPING
Genomic DNA was extracted from 5 ml of frozen whole blood using a DNA extraction kit (Tiangen Biotech Co. Ltd, Beijing, China) according to the manufacturer's protocol. Primers for the polymerase chain reaction (PCR) were designed from the published VDBP gene sequence, 14 and the VDBP gene was amplified using a commercially available PCR reaction mix (Takara Bio Inc., Dalian, Japan), according to the manufacturer's instructions. The primer pairs used to amplify the VDBP gene were: upstream, 5′-TAATGAGCAAATGAAAGAAG-3′; downstream, 5′-AATCACAGTAAAGAGG AGGT-3′. The cycling programme involved preliminary denaturation at 94°C for 5 min, followed by 35 cycles of denaturation at 94°C for 30 s, annealing at 48°C for 30 s, and elongation at 72°C for 30 s, followed by a final elongation step at 72°C for 7 min.
The PCR product was genotyped by restriction fragment length polymorphism analysis, involving overnight restriction enzyme digestion at 37°C with the HaeIII and StyI restriction enzymes. If the VDBP-1S allele is present, the HaeIII enzyme produces bands of 295 and 93 bp, whereas if the VDBP-2 allele is present the StyI enzyme produces bands of 304 and 84 bp; the VDBP-1F variant remains uncut with both enzyme digests. The digested DNA fragments were then resolved on a 2.0% agarose gel with 0.2 µg/ml ethidium bromide.
STATISTICAL ANALYSES
All statistical analyses were carried out using the SPSS ® statistical package, version 13.0 Vitamin D binding protein variants and COPD (SPSS Inc., Chicago, IL, USA) for Windows ® . The genotype and allele frequencies for each patient and control were obtained by direct counting of bands resulting from the restriction enzyme digests. Comparisons of the distributions of the allele and genotype frequencies were performed using the χ 2 -test. The relative risk associated with rare alleles was estimated as an odds ratio (OR) with a 95% confidence interval (CI). A P-value < 0.05 was considered to be statistically significant.
Results
In total, 100 patients with COPD and 100 healthy control subjects were recruited into the study. Lung function test results are shown in Table 1 . The groups were matched in terms of age and gender. The distribution of the six major genotypes of VDBP in the control and COPD groups is presented in Table 2 . The proportion of VDBP-1F homozygotes was significantly higher in COPD patients than control subjects (P = 0.0003; OR (95% CI) versus all other genotypes of 3.08 [1.498, 6.347]). The proportion of VDBP-2 homozygotes was significantly lower in COPD patients than in control subjects (P = 0.0017; OR [95% CI] versus all other genotypes of 0.215 [0.060, 0.772]). The distribution frequency of the three alleles is shown in Table 3 . In the COPD group of patients, the frequency of the VDBP-1F allele was significantly higher (P = 0.0035) and the frequency of VDBP-2 was significantly lower (P = 0.0003) than for the healthy control group. There were no significant between-group differences in the frequency distribution of the VDBP-1S allele.
Discussion
Neutrophils have been assumed to play a key role in the pathogenesis of COPD. 15 Thus, variation in genes with a function 10 and it undergoes conversion to a potent macrophageactivating factor (MAF) as a result of the removal of specific glycosylated moieties. 9 It has been shown, however, that there are no differences between the three VDBP isoforms in terms of their ability to induce neutrophil chemotaxis. 16 The present study showed that the proportion of COPD patients with the homozygous VDBP-1F genotype was significantly higher than for control subjects, suggesting that VDBP-1F homozygosity may be a risk factor for COPD. This confirms data from a study in a Japanese population. 17 Previous studies on VDBP gene polymorphism have shown varying results in association of this polymorphism with the risk of COPD. For example, Kueppers et al. 18 showed that the frequency of the homozygous VDBP-2 genotype was only 0.01 in patients with COPD compared with 0.05 in control subjects, but the study performed by Kauffmann et al. 19 failed to confirm this result. Subsequently, Horne et al. 7 showed that the frequency of the homozygous VDBP-1F genotype in patients with COPD was 0.06 and was significantly greater than in control subjects (P = 0.01; relative risk, 4.8). It has also been noted that the frequencies of the VDBP alleles vary with ethnicity. 7, 20, 21 The present study found that VDBP-2 homozygosity seemed to exert a protective effect with respect to COPD, a result that has also been reported by Schellenberg et al. 16 Besides increasing neutrophil chemotaxis, when VDBP is converted to a MAF (as described above) it increases the activation of macrophages at the sites of inflammation. According to Yamamoto and Naraparaju 22 both the VDBP-1S and VDBP-1F isoforms contain identical side-chain structures, while the VDBP-2 isoform has alternate sugar moieties. The VDBP2 protein has two different forms; the less prevalent form (10%) displays a shorter side chain that can be modified to become a MAF. Most of the VDBP2 protein molecules undergo no glycosylation and are incapable of being converted to a MAF. The low glycosylation level in homozygous VDBP2 individuals could result in less MAF being produced and, therefore, less pulmonary inflammation. 22 This could perhaps provide one explanation for the protective effect of the VDBP2-2 genotype against COPD found in the present study.
In conclusion, the data of the present study suggest that the 1F allele of the VDBP gene may be a risk factor for COPD, while the presence of the 2 allele may be one of the protective factors against COPD.
